Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
re.Mind Capital is an early-stage investment organization founded in 2020, dedicated to addressing mental health and brain health challenges. As part of Christian Angermayer's Apeiron Investment Group, it serves as the mental health venture capital arm, focusing on innovative solutions that promote human flourishing. The firm operates globally, with a particular emphasis on North America and Europe.
The firm has a clear mission to support founders who are pioneering advancements in areas such as brain-computer interfaces, new pharmacological treatments, and digital mental health solutions. re.Mind Capital aims to back science- and technology-led companies that demonstrate a clear path to clinical or therapeutic impact. The firm emphasizes a science-driven approach, leveraging the broader Apeiron network to provide insights and connections that enhance clinical outcomes.
Notable milestones include the establishment of a diverse portfolio that spans various sectors within mental health and brain health. The firm is committed to investing in breakthroughs that emerge from the convergence of neuroscience, pharmacology, digital health, and artificial intelligence.
re.Mind Capital focuses on early-stage investments in companies that are innovating within the mental health and brain health sectors. The firm targets a range of key areas, including brain-computer interfaces, personalized treatment modalities, and novel pharmacological approaches. Their investment strategy is centered on supporting science- and technology-led companies that have a clear path to clinical or therapeutic impact.
The firm is particularly interested in startups that are developing solutions in neuroscience, digital mental health, neurotechnology, psychedelics, precision psychiatry, and neuromodulation. Geographic focus includes North America and Europe, with a commitment to addressing pressing challenges in mental well-being. While specific check sizes are not disclosed, the firm is known to invest in seed, Series A, and growth equity stages.
re.Mind Capital seeks founders who are tackling significant challenges in mental health and brain health, emphasizing the importance of innovation that promotes human flourishing. The firm does not publish a standard application process, but encourages concise, science-driven outreach to their team email.
re.Mind Capital has built a diverse portfolio of companies focused on mental health and brain health innovations. Key portfolio companies include:
This portfolio reflects re.Mind Capital's commitment to investing in groundbreaking solutions that address major mental and neurological health challenges.
Christian Angermayer — Co-founder & General Partner. Angermayer is the founder and investor behind Apeiron Investment Group and has a strong background in investments related to psychedelics and life sciences.
Max de Vere — Co-founder & General Partner. De Vere is listed on re.Mind's official team page and has a background in venture capital and investment.
Jan Hardorp — Co-founder & General Partner / Founding Partner. Hardorp is also featured on the official team page and has experience in early-stage investments.
Joao Barbosa da Silva — Investment Associate. Barbosa da Silva is part of the re.Mind team and contributes to the firm's investment activities.
To pitch to re.Mind Capital, founders should use the email address team@remind.vc. A concise pitch deck that highlights the scientific and technological aspects of the startup is recommended. While there is no formal application process disclosed, the firm operates on a rolling basis, allowing for ongoing submissions.
Founders should expect a response time that varies based on the volume of inquiries, so timely follow-ups may be beneficial. Warm introductions are not explicitly required, but they can enhance the chances of engagement.
In 2023, re.Mind Capital's portfolio company Alto Neuroscience secured $60 million in financing, highlighting the firm's active involvement in supporting innovative mental health solutions.
As part of the Apeiron Investment Group, re.Mind Capital continues to expand its influence in the mental health sector, focusing on groundbreaking technologies and therapies.
What are re.Mind Capital's investment criteria?
re.Mind Capital invests in early-stage companies focused on mental health and brain health innovations. They look for science- and technology-led companies with a clear path to clinical or therapeutic impact.
How can I pitch to re.Mind Capital?
Founders can pitch to re.Mind Capital by sending an email to team@remind.vc. A concise, science-driven outreach is recommended.
What makes re.Mind Capital different from other VCs?
re.Mind Capital specializes in mental health and brain health, leveraging the broader Apeiron network to provide strategic support and insights to its portfolio companies.
What is the geographic scope of re.Mind Capital's investments?
The firm invests globally, with a focus on North America and Europe.
What stages does re.Mind Capital invest in?
re.Mind Capital invests in seed, Series A, and growth equity stages.
What is the decision timeline for investments?
The firm does not disclose a specific decision timeline, but they operate on a rolling application cycle.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.